Scientific Affairs LLC, 2175 Eldorado Drive, Atlanta, GA 30345, USA.
Infect Dis Clin North Am. 2019 Sep;33(3):611-628. doi: 10.1016/j.idc.2019.04.001. Epub 2019 Jun 22.
Profound changes in technology have revolutionized laboratory testing for human immunodeficiency virus (HIV) since the first laboratory enzyme immunoassays that detected only immunoglobulin G (IgG) antibodies. Instrumented fourth-generation random-access chemiluminescent assays are now recommended for initial screening because they become reactive in as little as 2 weeks after infection. Using HIV-1 RNA viral load assays after a reactive initial test could confirm infection and provide useful clinical information. Early initiation of antiretroviral therapy and use of preexposure prophylaxis can alter the evolution of biomarkers and assay reactivity, leading to ambiguous test results.
自首次用于检测仅免疫球蛋白 G(IgG)抗体的实验室酶免疫测定以来,技术的深刻变革彻底革新了人类免疫缺陷病毒(HIV)的实验室检测。目前推荐使用仪器化第四代随机访问化学发光测定法进行初始筛查,因为其在感染后短短 2 周内即可呈现反应性。在初始检测呈反应性后使用 HIV-1 RNA 病毒载量测定法可以确认感染并提供有用的临床信息。早期开始抗逆转录病毒治疗并使用暴露前预防措施可以改变生物标志物和检测反应性的演变,导致检测结果模棱两可。